1′S-1′-acetoxyeugenol acetate: A novel phenylpropanoid from Alpinia conchigera enhances the apoptotic effects of paclitaxel in MCF-7 cells through NF-κB inactivation

Anti-Cancer Drugs

Volumn 22, Issue 5, 2011, Pages 424-434

  Aun, Lionel Lian ^a   Azmi, Mohamad Nurul ^b   Ibrahim, Halijah ^a   Awang, Khalijah ^b   Nagoor, Noor Hasima ^a  

^a UNIVERSITY OF MALAYA   (Malaysia)

^b Centre for Natural Product Research and Drug Discovery (CENAR)   (Malaysia)

Author keywords

Acetoxyeugenol acetate; Alpinia conchigera; apoptosis; cancer; nuclear factor kappaB

Indexed keywords

1'S 1' ACETOXYEUGENOL ACETATE; ANTINEOPLASTIC AGENT; EUGENOL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PACLITAXEL; PLANT EXTRACT; UNCLASSIFIED DRUG; 1' ACETOXYEUGENOL; 1'-ACETOXYEUGENOL; CHUK PROTEIN, HUMAN; DRUG DERIVATIVE; HERBACEOUS AGENT; I KAPPA B KINASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE;

ALPINIA; ALPINIA CONCHIGERA; APOPTOSIS; ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENTIATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; BREAST TUMOR; CELL LINE; CHEMISTRY; DRUG ANTAGONISM; DRUG EFFECT; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METHODOLOGY; MICROARRAY ANALYSIS; PATHOLOGY; RHIZOME; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ALPINIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; DRUG SYNERGISM; DRUGS, CHINESE HERBAL; EPITHELIAL CELLS; EUGENOL; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; I-KAPPA B KINASE; MICROARRAY ANALYSIS; NF-KAPPA B; PACLITAXEL; POLY(ADP-RIBOSE) POLYMERASES; RHIZOME; SIGNAL TRANSDUCTION;

EID: 79955057806     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/CAD.0b013e328343cbe6     Document Type: Article

References (42)

1. Baselga J, Mendelsohn J. The epidermal growth factor receptor as a target for therapy in breast carcinoma. Breast Cancer Res Treat 1994; 29:127-138. (Pubitemid 24104844)
2. Kolonel LN, Altshuler D, Henderson BE. The multiethnic cohort study: exploring genes, lifestyle and cancer risk. Nat Rev Cancer 2004; 4:519-527. (Pubitemid 38868621)
3. Matsuda H, Ando S, Morikawa T, Kataoka S, Yoshikawa M. Structure-activity relationships of 1'S-1'-acetoxychavicol acetate for inhibitory effect on NO production in lipopolisaccharide-activated mouse peritoneal macrophages. Bioorg Med Chem 2005; 15:1949-1953. (Pubitemid 40380764)
4. Burkill IH. A dictionary of the economic products of the Malay peninsular. 2nd ed. Vol. 1 and 2. Kuala Lumpur, Malaysia: Ministry of Agriculture and Cooperatives; 1966.
5. Hasima NN, Lionel ILA, Azmi MN, Nazif AA, Thirthagiri E, Halijah I, Khalijah A. 1'S-1'-Acetoxyeugenol acetate: a new chemotherapeutic natural compound against MCF-7 human breast cancer cells. Phytomedicine 2010; 17:935-939. doi:10.1016/j.phymed.2010.03.011.
6. Campbell CT, Prince M, Landry GM, Kha V, Kleiner HE. Pro-apoptotic effects of 1'-acetoxychavicol acetate on in human breast carcinoma cells. Toxlet 2007; 173:151-160. (Pubitemid 47391547)
7. Ichikawa H, Takada Y, Murakami A, Aggarwal BB. Identification of a novel blocker of IkBa kinase that enhances cellular apoptosis and inhibits cellular invasion through suppression of NF-kB regulated gene products. J Immunol 2005; 174:7383-7392. (Pubitemid 40705709)
8. Kondo A, Ohigashi H, Murakami A. A potent inhibitor of tumor-promoterinduced Epstein Barr virus activation, 1'-acetoxychavicol acetate from Languas galanga, a traditional Thai condiment. Biosci Biotechnol Biochem 1993; 57:1344-1345.
9. Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kB and nuclear factor-kB-regulated gene products in IFNa- sensitive and IFN-a-resistant human bladder cancer cells. Mol Cancer Ther 2007; 6:1022-1030. (Pubitemid 46554572)
10. Aggarwal BB. Nuclear factor-kB: the enemy within. Cancer Cell 2004; 6:203-208.
11. Sovak MA, Bellas RE, Kim DW, Zanieski GJ, Rogers AE, Traish AM, Sonenshein GE. Abberant nuclear factor-kappaB/Rel expression and the pathogenesis of breast cancer. J Clin Invest 1997; 100:2952-2960. (Pubitemid 28022831)
12. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 2000; 19:5498-5406.
13. Cogswell PC, Gutteridge DC, Funkhouser WK, Baldwin AS Jr. Selective activation of NF-kB subunits in human breast cancer: potential roles for /p52 and for Bcl-3. Oncogene 2000; 19:1123-1131. (Pubitemid 30157541)
14. Zhou S, Eppenberger-Castori S, Eppenberger U, Benz CC. The NF-kB pathway and endocrine-resistant breast cancer. Endocr Relat Cancer 2005; 12:S37-S46. (Pubitemid 41398155)
15. Sethi G, Aggarwal BB. Role of NF-kB and NF-kB regulated gene products in chemoresistance and radioresistance. Curr Cancer Ther Rev 2006; 2:115-125. (Pubitemid 44082893)
16. Nakanishi C, Toi M. Nuclear factor-kB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-209.
17. Aggarwal BB. Apoptosis and nuclear factor-kB: a tale of association anddissociation. Biochem Pharmacol 2000; 60:1033-1039.
18. Zhao L, Wientjes GM, Au JLS. Evaluation of combination chemotherapy: integration of nonlinear regression, curve shift, isobologram, and combination index analyses. Clin Cancer Res 2004; 10:7994-7904.
19. Ito K, Nakazato T, Xian MJ, Yamada T, Hozumi N, Murakami A, et al. 1'-acetoxychavicol acetate is a novel nuclear factor kB inhibitor with significant activity against multiple myeloma in vitro and in vivo. Cancer Res 2005; 65:4417-4424. (Pubitemid 40775681)
20. Ichikawa H, Murakami A, Aggarwal BB. 1'-acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kB activation. Mol Cancer Res 2006; 4:275-281.
21. Fujioka S, Sclabas GM, Schmidt C, FrederickWA, Dong QG, Abbruzzese JL, et al. Function of nuclear factor kB in pancreatic cancer metastasis. Clin Cancer Res 2003; 9:346-354. (Pubitemid 36109751)
22. Bos J. Ras oncogenes in human cancer: a review. Cancer Res 1989; 49:4682-4689. (Pubitemid 19213607)
23. Kuphal S, Poser I, Jobin C, Hellerbrand C, Bosserhoff AK. Loss of E-cadherin leads to upregulation of NF-kB activity in malignant melanoma. Oncogene 2004; 23:8509-8519. (Pubitemid 39540801)
24. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-kB activity. Annu Rev Immunol 2000; 18:621-663. (Pubitemid 30365393)
25. Beinke S, Ley SC. Review article: functions of NF-kB 1 and NF-kB 2in immune cell biology. J Biochem 2004; 382:393-309.
26. Yang J, Lin Y, Guo Z, Beinke S, Ley SC. The essential role of MEKK3 in TNF-induced NF-kB activation. Nat Immunol 2001; 3:20-26.
27. Takaesu G, Surabhi RM, Park KJ, Ninomiya-Tsuji J, Matsumoto K, Gaynor RB. TAK1 is critical for IkB kinase-mediated activation of the NF-kB pathway. J Mol Biol 2003; 326:105-115. (Pubitemid 36279361)
28. Senftleben U, Cao Y, Xiao G, Greten FR, Krahn G, Bonizzi G, et al. Activation of IKKa of a second evolutionary conserved NF-kB signaling pathway. Science 2001; 293:1495-1499. (Pubitemid 32801552)
29. Xiao G, Harhaj EW, Sun SC. NF-kB -inducing kinase regulates the processing of NF-kB 2 p100. Mol Cell 2001; 7:401-409. (Pubitemid 32206507)
30. Jazirehi AR, Gan SH, De Vos S, Emmanouilides C, Bonavida B. Rituximab (anti CD20) selectively modifies Bcl-xL and Apaf-1 expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther 2003; 2:1183-1193.
31. Agagrwal BB, Ichikawa H, Garodia P. From traditional Ayurvedic medicine to modern medicine: identification of therapeutic targets for suppression of inflammation and cancer. Expert Opin Ther Targets 2006; 10:87-118. (Pubitemid 43263269)
32. Abbrezzese JL, Lippman SM. The convergence of cancer prevention and therapy in early-phase clinical drug development. Cancer Cell 2004; 6:321-326. (Pubitemid 39361433)
33. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM. Suppression of TNF-a induced apoptosis by NF-kB. Science 1996; 274:787-789. (Pubitemid 26398260)
34. Wang CY, Mayo MW, Baldwin AS Jr. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kB. Science 1996; 274:784-787. (Pubitemid 26398259)
35. Loercher A, Tin LL, Ricker JL, Howard A, Geoghegen J, Chen Z, et al. Nuclear factor-kB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004; 64:6511-6523. (Pubitemid 39297908)
36. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumour necrosis factor a in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene 2001; 20:4519-4527. (Pubitemid 32772434)
37. Barnes PJ, Karin M. Nuclear factor-kB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 1997; 336:1066-1071. (Pubitemid 27163860)
38. Tak PP, Firestein GS. NF-kB: a key role in inflammatory diseases. J Clin Invest 2001; 107:7-11. (Pubitemid 32047405)
39. Collins T, Cybulsky MI. NF-kB: pivotal mediator or innocent bystander in atherogenesis? J Clin Invest 2001; 107:255-264. (Pubitemid 32157955)
40. Mattson MP, Camandola S. NF-kB in neuronal plasticity and neurodegenerative disorders. J Clin Invest 2001; 107:247-254. (Pubitemid 32162153)
41. Podolsky DK. Inflammatory bowel disease. N Eng J Med 1991; 325:928-937.
42. Carrick S, Parker S, Thornton CE, Ghersi D, Simes J, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2009; 2:CD003372.